Phase I
Here’s a look at the top clinical trial news from last week, with updates from Neon, GSK, Biohaven, and more.
In addition to the three preclinical assets from Novartis, Gilead has recently entered into deals to develop therapies for HIV, RA and NASH.
In its third installment of the Good Pharma Scorecard, Roche and Novo Nordisk scored perfect marks in overall trial transparency, while Johnson & Johnson slipped from the high spot on the previous ranking.
Tau Morphomer™ is the focus of a partnership with Eli Lilly and Company
Pharma and biotech companies from across the globe provide updates on their pipelines and corporate strategy.
There’s been quite a few small and mid-sized deals announced today. Let’s take a look at four of them.
More than 600 employees will lose their jobs as the companies reshape their corporate strategies.
The asset, LYT-100, is an oral compound that has shown anti-fibrotic and anti-inflammatory properties.
Four years ago, Takeda Pharmaceutical Company and The Center for iPS Cell Research and Application (CiRA) at Kyoto University established a 10-year joint research program. Today, the organizations made an announcement.
Phase 1/2 trial to be HOOKIPA’s first clinical trial in immuno-oncology
PRESS RELEASES